ATE419245T1 - Cinnoline verbindungen - Google Patents
Cinnoline verbindungenInfo
- Publication number
- ATE419245T1 ATE419245T1 AT01954175T AT01954175T ATE419245T1 AT E419245 T1 ATE419245 T1 AT E419245T1 AT 01954175 T AT01954175 T AT 01954175T AT 01954175 T AT01954175 T AT 01954175T AT E419245 T1 ATE419245 T1 AT E419245T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- sup
- alkyl
- represents hydrogen
- formula
- Prior art date
Links
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical class N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- -1 N-methylpiperazinly Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 125000005505 thiomorpholino group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00402255 | 2000-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE419245T1 true ATE419245T1 (de) | 2009-01-15 |
Family
ID=8173806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01954175T ATE419245T1 (de) | 2000-08-09 | 2001-08-07 | Cinnoline verbindungen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6887874B2 (de) |
| EP (1) | EP1309587B1 (de) |
| JP (1) | JP2004505966A (de) |
| KR (1) | KR100834823B1 (de) |
| CN (1) | CN1252065C (de) |
| AT (1) | ATE419245T1 (de) |
| AU (2) | AU2001276521B2 (de) |
| BR (1) | BR0113057A (de) |
| CA (1) | CA2415022A1 (de) |
| DE (1) | DE60137234D1 (de) |
| ES (1) | ES2317923T3 (de) |
| IL (2) | IL153805A0 (de) |
| MX (1) | MXPA02012943A (de) |
| NO (1) | NO326475B1 (de) |
| NZ (1) | NZ523388A (de) |
| WO (1) | WO2002012228A1 (de) |
| ZA (1) | ZA200300221B (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| PT1244647E (pt) * | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| AU2001235804A1 (en) | 2000-03-06 | 2001-09-17 | Astrazeneca Ab | Therapy |
| IL151626A0 (en) | 2000-04-07 | 2003-04-10 | Astrazeneca Ab | Quinazoline compounds |
| EP2292615A1 (de) * | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Chinazoline Verbindungen |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| RU2350618C2 (ru) * | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| SI1625121T1 (sl) | 2002-12-20 | 2010-04-30 | Pfizer Prod Inc | Derivati pirimidina za zdravljenje abnormalne rasti celic |
| GB0318422D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| MXPA06013164A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| EP1758887A1 (de) | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidinderivate zur behandlung von anormalem zellwachstum |
| MXPA06011658A (es) | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
| CA2578996A1 (en) * | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| RU2007131400A (ru) * | 2005-03-01 | 2009-04-10 | Вайет (Us) | Соединения циннолина и их применение в качестве модуляторов х-рецепторов печени |
| AU2007217474A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| WO2007100880A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| US8921533B2 (en) | 2011-07-25 | 2014-12-30 | Chromatin Technologies | Glycosylated valproic acid analogs and uses thereof |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| WO2014144715A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| CN104370825B (zh) * | 2014-09-29 | 2017-04-19 | 人福医药集团股份公司 | 作为激酶抑制剂的取代杂环化合物及其制备方法和用途 |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| EP3519816A4 (de) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | Verbindungen zur erhöhung der neuronalen plastizität |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| CN1252054C (zh) * | 1996-09-25 | 2006-04-19 | 曾尼卡有限公司 | 抑制生长因子的作用的喹啉衍生物 |
| AU719392B2 (en) | 1996-10-01 | 2000-05-11 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compounds |
| CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
-
2001
- 2001-08-07 IL IL15380501A patent/IL153805A0/xx unknown
- 2001-08-07 ES ES01954175T patent/ES2317923T3/es not_active Expired - Lifetime
- 2001-08-07 AU AU2001276521A patent/AU2001276521B2/en not_active Ceased
- 2001-08-07 CA CA002415022A patent/CA2415022A1/en not_active Abandoned
- 2001-08-07 US US10/333,592 patent/US6887874B2/en not_active Expired - Fee Related
- 2001-08-07 AU AU7652101A patent/AU7652101A/xx active Pending
- 2001-08-07 CN CNB018139167A patent/CN1252065C/zh not_active Expired - Fee Related
- 2001-08-07 AT AT01954175T patent/ATE419245T1/de not_active IP Right Cessation
- 2001-08-07 KR KR1020037001922A patent/KR100834823B1/ko not_active Expired - Fee Related
- 2001-08-07 BR BR0113057-9A patent/BR0113057A/pt not_active IP Right Cessation
- 2001-08-07 JP JP2002518203A patent/JP2004505966A/ja active Pending
- 2001-08-07 DE DE60137234T patent/DE60137234D1/de not_active Expired - Fee Related
- 2001-08-07 NZ NZ523388A patent/NZ523388A/en unknown
- 2001-08-07 EP EP01954175A patent/EP1309587B1/de not_active Expired - Lifetime
- 2001-08-07 WO PCT/GB2001/003533 patent/WO2002012228A1/en not_active Ceased
- 2001-08-07 MX MXPA02012943A patent/MXPA02012943A/es active IP Right Grant
-
2003
- 2003-01-05 IL IL153805A patent/IL153805A/en not_active IP Right Cessation
- 2003-01-08 ZA ZA200300221A patent/ZA200300221B/en unknown
- 2003-02-07 NO NO20030624A patent/NO326475B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100834823B1 (ko) | 2008-06-09 |
| NO20030624L (no) | 2003-04-07 |
| AU2001276521B2 (en) | 2006-05-25 |
| CN1446214A (zh) | 2003-10-01 |
| EP1309587B1 (de) | 2008-12-31 |
| US20030212055A1 (en) | 2003-11-13 |
| US6887874B2 (en) | 2005-05-03 |
| JP2004505966A (ja) | 2004-02-26 |
| NO20030624D0 (no) | 2003-02-07 |
| MXPA02012943A (es) | 2003-05-15 |
| KR20030022379A (ko) | 2003-03-15 |
| CN1252065C (zh) | 2006-04-19 |
| WO2002012228A1 (en) | 2002-02-14 |
| DE60137234D1 (de) | 2009-02-12 |
| IL153805A0 (en) | 2003-07-31 |
| ES2317923T3 (es) | 2009-05-01 |
| BR0113057A (pt) | 2003-07-08 |
| IL153805A (en) | 2009-05-04 |
| NZ523388A (en) | 2004-09-24 |
| CA2415022A1 (en) | 2002-02-14 |
| ZA200300221B (en) | 2004-04-08 |
| AU7652101A (en) | 2002-02-18 |
| NO326475B1 (no) | 2008-12-08 |
| EP1309587A1 (de) | 2003-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60137234D1 (de) | Cinnoline verbindungen | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| NO991423D0 (no) | Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGF | |
| MXPA03000252A (es) | Derivados de quinolina que tienen actividad de inhibicion de fcev. | |
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| CA2344290A1 (en) | Quinazoline derivatives | |
| MY129540A (en) | Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect | |
| DK0873319T3 (da) | Quinazolinderivater | |
| MXPA01004256A (es) | N-arilamidas del acido antranilico y del acido tioantranilico. | |
| ATE286501T1 (de) | Pyrimidinderivate | |
| NO305209B1 (no) | N-alkyl-2-substituerte ATP-analoger, slike forbindelser til fremstilling av terapeutikum, farmas°ytisk preparat inneholdende slike forbindelser, og deres anvendelse | |
| TW200517109A (en) | Substituted pyridinones | |
| RU2007110629A (ru) | Ингибиторы днк-пк | |
| NO20023932D0 (no) | Nye forbindelser | |
| BR0113078A (pt) | Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente | |
| JP2004517843A5 (de) | ||
| MX2022016263A (es) | Derivados de ciclobutil-urea. | |
| ATE401080T1 (de) | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs | |
| MY137835A (en) | Quinazoline derivatives as src tyrosine kinase inhibitors | |
| UA74341C2 (uk) | Похідні борелідину, які інгібують ангіогенез | |
| HUP0001773A2 (hu) | Szubsztituált tetrahidropiridinszármazékok, eljárás előállításukra, továbbá a vegyületeket tartalmazó gyógyászati készítmények | |
| JP2021523936A5 (de) | ||
| PL371520A1 (en) | New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds | |
| TH45291A (th) | อนุพันธ์ไซคลิคเอมีน | |
| TH65936A (th) | อนุพันธ์ของ n-[เฟนิล(พิเพอริดิน-2-อิล)เมธิล]เบนแซมีด, การเตรียมของอนุพันธ์เหล่านี้และการใช้ของอนุพันธ์เหล่านี้ในการรักษาโรค |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |